New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Study reveals potential target for precision colorectal cancer treatment

Study reveals potential target for precision colorectal cancer treatment

by Mallory Locklear,Yale UniversityFlowchart outlining the study. A: Metabolomics data collection and analysis; including targeted analysis of metabolites involved in ferroptosis pathways; B: Id
Oncology February 18,2024
Study reveals potential target for precision colorectal cancer treatment

Study reveals potential target for precision colorectal cancer treatment

by Mallory Locklear,Yale UniversityFlowchart outlining the study. A: Metabolomics data collection and analysis; including targeted analysis of metabolites involved in ferroptosis pathways; B: Id
Oncology February 18,2024
Researchers make miniature 'bone marrows in a dish' to improve anti-cancer treatments

Researchers make miniature 'bone marrows in a dish' to improve anti-cancer treatments

by University of BirminghamA cross section of a mini bone marrow organoids showing cells that produce blood platelets, in a network of blood vessels. Credit: Dr A Khan, University of BirminghamSc
Oncology February 18,2024
Researchers make miniature 'bone marrows in a dish' to improve anti-cancer treatments

Researchers make miniature 'bone marrows in a dish' to improve anti-cancer treatments

by University of BirminghamA cross section of a mini bone marrow organoids showing cells that produce blood platelets, in a network of blood vessels. Credit: Dr A Khan, University of BirminghamSc
Oncology February 18,2024
Drugs to prevent anxiety, stress reactions and inflammation found to reduce risk of metastases after tumor surgery

Drugs to prevent anxiety, stress reactions and inflammation found to reduce risk of metastases after tumor surgery

by Tel Aviv UniversityStress responses and reciprocal stress–cancer interactions. Credit:European Journal of Surgical Oncology(2022). DOI: 10.1016/j.ejso.2022.10.013A short, simple an
Oncology February 18,2024
Drugs to prevent anxiety, stress reactions and inflammation found to reduce risk of metastases after tumor surgery

Drugs to prevent anxiety, stress reactions and inflammation found to reduce risk of metastases after tumor surgery

by Tel Aviv UniversityStress responses and reciprocal stress–cancer interactions. Credit:European Journal of Surgical Oncology(2022). DOI: 10.1016/j.ejso.2022.10.013A short, simple an
Oncology February 18,2024
Researchers identify a better biomarker for an aggressive and fatal liver cancer

Researchers identify a better biomarker for an aggressive and fatal liver cancer

by Ryn Thorn,Medical University of South CarolinaDr. Anand Mehta (left) and Dr. Shaaron Ochoa-Rios (right) in the Mehta laboratory at the Medical University of South Carolina. Credit: Medical Un
Oncology February 18,2024
Researchers identify a better biomarker for an aggressive and fatal liver cancer

Researchers identify a better biomarker for an aggressive and fatal liver cancer

by Ryn Thorn,Medical University of South CarolinaDr. Anand Mehta (left) and Dr. Shaaron Ochoa-Rios (right) in the Mehta laboratory at the Medical University of South Carolina. Credit: Medical Un
Oncology February 18,2024
Ultrasound May Be Useful to Assess Subclinical Synovial Inflammation in Hemophilia

Ultrasound May Be Useful to Assess Subclinical Synovial Inflammation in Hemophilia

December 2023Ruth Jessen Hickman, MDA study published inHaemophiliahighlights the potential utility of ultrasound screenings to assess preclinical joint damage in patients with hemophilia
Orthopedics & Sports medicine February 18,2024
Ultrasound May Be Useful to Assess Subclinical Synovial Inflammation in Hemophilia

Ultrasound May Be Useful to Assess Subclinical Synovial Inflammation in Hemophilia

December 2023Ruth Jessen Hickman, MDA study published inHaemophiliahighlights the potential utility of ultrasound screenings to assess preclinical joint damage in patients with hemophilia
Orthopedics & Sports medicine February 18,2024
Rituximab Maintenance Effective for Autoimmune Cytopenias

Rituximab Maintenance Effective for Autoimmune Cytopenias

August 2023Thomas R. CollinsPatients with autoimmune cytopenias had longer durations of response after induction treatment with rituximab when rituximab was continued as maintenance therapy compared w
Oncology February 18,2024
Rituximab Maintenance Effective for Autoimmune Cytopenias

Rituximab Maintenance Effective for Autoimmune Cytopenias

August 2023Thomas R. CollinsPatients with autoimmune cytopenias had longer durations of response after induction treatment with rituximab when rituximab was continued as maintenance therapy compared w
Oncology February 18,2024
Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Universal risk predictor for cardiovascular disease, suitable for use in both primary and secondary prevention, would streamline risk assessmentPublishedJanuary 29, 2024EPIDEMIOLOGYResearchers from th
Oncology February 18,2024
Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Universal risk predictor for cardiovascular disease, suitable for use in both primary and secondary prevention, would streamline risk assessmentPublishedJanuary 29, 2024EPIDEMIOLOGYResearchers from th
Oncology February 18,2024
Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure

Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure

February 2024Lara C. Pullen, PhDNew research reveals that patients with thrombocytopenia, thrombosis, and very high D-dimer levels could have platelet-activating vaccine-induced immune thrombocytopeni
Oncology February 18,2024
Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure

Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure

February 2024Lara C. Pullen, PhDNew research reveals that patients with thrombocytopenia, thrombosis, and very high D-dimer levels could have platelet-activating vaccine-induced immune thrombocytopeni
Oncology February 18,2024
New study flips the script on liver cancer

New study flips the script on liver cancer

by University of California - San DiegoUC San Diego scientists find the protein ATF4 prevents liver damage and its progression to cancer by blocking ferroptosis, an iron-dependent form of liver c
Oncology February 18,2024
New study flips the script on liver cancer

New study flips the script on liver cancer

by University of California - San DiegoUC San Diego scientists find the protein ATF4 prevents liver damage and its progression to cancer by blocking ferroptosis, an iron-dependent form of liver c
Oncology February 18,2024
Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m
Oncology February 18,2024
Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m
Oncology February 18,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com